IPA.V - ImmunoPrecise Antibodies Ltd


#142

ImmunoPrecise Announces Phage DisplayBased Antibody Discovery Platforms

VICTORIA, Oct. 2, 2018

VICTORIA, Oct. 2, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage libraries to their growing service offeringsthrough their recent expansion in Europe. Through construction and screening of scFv and VHH phage display libraries, ImmunoPrecise is able to generate monoclonal antibodies, in a diverse range of animal species, against complex protein structures.

The Company offers access to proprietary in-house human and llama VHH phage libraries, applicable for non-immunogenic and toxic targets, the construction of custom immune libraries prepared from a diverse range of animal species, and synthetic phage libraries generated for state-of-the-art humanization and affinity maturation procedures to optimize lead candidates for clinical trials. Access to their royalty-free human scFv and llama VHH repertoires, along with expertise in protein and antibody engineering, positions the Company as a desirable provider for bispecific antibody development.

A Powerful Method for Therapeutic Antibody Development

Antibody phage display uses genetically engineered bacteriophage to express a single antibody fragment sequence on their outer surface, allowing isolation of the antibody-bound phage with the required characteristics by selection on the target.

Through phage display, ImmunoPrecise is able to offer another avenue of therapeutic antibody discovery; positioning them as a full-service CRO offering the full continuum of antibody discovery, manufacturing and engineering, to deliver a broad and diverse panel of antibodies for therapeutic campaigns.

Phage Advantages

Diversity - Specificity - Stability

  • Access to naïve and disease human, and naïve llama immune repertoires from in-house libraries
  • Custom immune libraries prepared from blood, spleen, lymph nodes, and bone marrow of a diverse range of immunized animals
  • Llama VHH antibodies offer high stability and small size
  • Allows high specificity selection to obtain a large diverse, highly specific antibody repertoire for full characterization
  • Unlimited re-screening of the library repertoires
  • Library-derived sequences for bispecific antibody development in multiple formats

#143

Le support à 0.83$ vient de briser…on s’en va vers le prochain support à 0.72$ sinon le prochain est à 0.54$.

À suivre


#144

ImmunoPrecise Signs Large Pharma Antibody Development Agreement

VICTORIA, Oct. 9, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed an agreement and initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company, to discover novel antibodies using ImmunoPrecise’s proprietary hybridoma technology.

ImmunoPrecise’s hybridoma platform allows for the selection of rare and slow-growing, IgG positive, monoclonal hybridomas in a semi-solid media format. Coupled with proprietary and abbreviated immunization regimes, the ability to sort cells and characterize and optimize lead candidates, ImmunoPrecise’s platform allows for streamlined processes, condensed timelines, and the early identification of developability issues, mitigating the risk of significant losses in time and money.

Under this multi-year development agreement, this global pharmaceutical company receives contract research services using ImmunoPrecise’s methods of discovering and developing antibodies in OmniAb® transgenic animals (Ligand Pharmaceuticals, NASDAQ: LGND), and intellectual property rights to develop and commercialize any resulting therapeutics.

The Agreement stipulates certain confidential provisions, including, at this stage, the pharmaceutical company’s identity, target and the monetary size of contract.

ImmunoPrecise is currently in negotiations with several top 10 global pharmaceutical companies investigating the use of ImmunoPrecise’s three full-service platforms, its advanced hybridoma platform, its proprietary and high demand B-cell selectplatform, and its phage display library platform. All three can be optimally leveraged for antibody discovery using various transgenic and wild-type animal strains.

“ImmunoPrecise can uniquely leverage three powerful platforms for antibody discovery to offer comprehensive campaigns that have the potential to deliver the antibody sequence diversity required to rapidly select the best lead candidates for further advancement” said Jennifer Bath, CEO and President of ImmunoPrecise Antibodies. "We’ve seen very strong interest in our diverse line of development platforms from a number of leading global pharmaceutical and biotech companies. "


#145

La baisse a été de relativement courte durée, avec le titre qui a clôturé a 0.88 vendredi et qui est maintenant de retour dans les bas 0.90. L’annonce d’un gros contrat (voir @SimB) le ramènera probablement au dessus de la barre des 1.00 sous peu.


#146

On a flirté brièvement avec le support à 0.72$ pour finir à .74$. Si 0.72$ brise on s’en va au prochain support à 0.54$ ce qui pourrait donner un point d’entrée intéressant


#147

ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform

VICTORIA, Oct. 29, 2018 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is excited to expand its immunization services through our recent growth in Europe. Our advanced genetic immunization strategies are applicable in multiple species, including transgenics, and across all discovery platforms. We have developed our genetic immunization protocol with our proprietary vectors to meet the growing demand for therapeutic antibodies against challenging, conformation-sensitive drug targets.

Through our in-house developed vectors, our protocol produces native protein with appropriate post-transcriptional modifications in vivo. Clients are not subject to downstream milestones or royalties, and bypass the requirement to purify protein or synthesize peptide for immunization.

Custom Developed Antibodies for Difficult Targets

Genetic immunization is a recommended protocol to compliment challenging campaigns against complex protein classes, such as GPCRs and ion channels. It overcomes the conformation obstacles of difficult antigens making it an ideal immunization platform in therapeutic discovery campaigns.

Genetic Advantage:

  • Overcomes conformational obstacles of complex transmembrane protein classes (e.g. GPCRs and ion channels)
  • Successful in multiple species, including transgenics
  • Time-saving when compared with traditional protein-based immunizations, since it avoids the lengthy process of expressing and purifying the immunogen

“ModiQuest’s long-standing expertise in advanced genetic immunization technologies is a strategic addition, designed specifically to deliver an unprecedented and growing arsenal of immunization approaches to tackle challenging therapeutic targets”, stated ImmunoPrecise’s President and CEO, Dr. Jennifer Bath.

ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform (CNW Group/ImmunoPrecise Antibodies Ltd.)

Debt Settlement

ImmunoPrecise announces that it has settled $1,377,000 of previously issued debentures by issuing 1,377,000 Units at a price of $1.00 per Unit (the “Debt Settlement”). The purpose of the Debt Settlement is to shore up ImmunoPrecise’s balance sheet by removing ongoing debt obligations related to $1,377,000of debentures.

Each Unit consists of one common share (a “Share”) of ImmunoPrecise and one share purchase warrant (a “Warrant”) of ImmuoPrecise, with each Warrant entitling the holder to purchase an additional Share at a price of $1.25 for a period of two years from the date of issue. ImmunoPrecise will have the right to accelerate the expiry date of the warrants provided that ImmunoPrecise’s volume weighted average price trades at a price equal to or greater than $1.75 for a period of 20 consecutive days. In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after ImmunoPrecise issues a news release announcing that it has elected to exercise this acceleration right

Settlement with Crossbeta

ImmunoPrecise and Crossbeta Biosciences B.V (“Crossbeta”) have entered into a settlement agreement in connection with the previously announced letter of intent entered into by the parties. Under the terms of the settlement agreement, ImmunoPrecise has agreed to pay EUR 37,000 to Crossbeta, and either (i) issue to Crossbeta such number of common shares equal to EUR 40,700 divided by the Market Price of ImmunoPrecise’s shares or (ii) pay to Crossbeta a cash payment of EUR 40,700.


#148

Un collaborateur d’EspaceMC, Paul Andreola, s’ajoute au conseil d’administration d’ImmunoPrecise :

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN that the annual general meeting (the “Meeting”) of the shareholders of
ImmunoPrecise Antibodies Ltd. (the “Company”) will be held at 704 – 595 Howe Street, Vancouver, BC,
V6C 2T5 on Tuesday, November 20, 2018 at 11:00 a.m. (PST) for the following purposes:
1. to set the number of directors at six (6) persons;
2. to elect Jennifer Bath, James Kuo, Greg Smith, Robert Beecroft, Robert Burke and Paul Andreola as
directors of the Company for the ensuing year;

Avec ses 30 années d’expérience, je suis sûr qu’il sera d’une aide précieuse pour aider la compagnie à adopter les bonnes stratégies entourant les marchés de capitaux. Il est aussi actionnaire important de la compagnie alors ses intérêts seront sans doute alignés avec ceux des actionnaires.


#149

Le marché a pas l’air d’accord avec toi en tout cas


#150

Il a rebondi exactement sur son support à 0.72$


#151

Si le marché était tout le temps d’accord avec moi, il n’y aurait jamais d’opportunité et ce ne serait pas un marché.

J’aime le fait que des détenteurs de la debenture convertible aient accepté de convertir à un prix de 1$ l’action pour 1.377M$ alors que le titre se transigeait sous les 0.80$. Les démarches pour convertir avaient été entreprise avant la récente chute mais de toute façon avec un horizon moindrement long terme, les fluctuations du marché ne changent rien à la thèse ni au potentiel de l’entreprise.


#152

Parfaitement d’accord avec toi, j’étais juste un peu amer que le titre soit down de 8-10% aujourd’hui. J’ai rien vu a date avec cette entreprise qui me fait peur.